The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALKERMES PLC | SHS | G01767105 | 170,697 | 2,799,690 | SH | SOLE | 2,675,890 | 0 | 123,800 | ||
NORTHWEST BIOTHERAPEUTICS INC | Common | 66737P600 | 69,131 | 9,379,987 | SH | SOLE | 8,604,987 | 0 | 775,000 | ||
PROTHENA CORP PLC | SHS | G72800108 | 141,430 | 3,708,171 | SH | SOLE | 3,486,171 | 0 | 222,000 | ||
REYNOLDS AMERICAN INC | Common | 761713106 | 323,082 | 4,688,458 | SH | SOLE | 4,336,049 | 0 | 352,409 |